These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


417 related items for PubMed ID: 16187699

  • 1. The impact of losartan on the lifetime incidence of ESRD and costs in Mexico.
    Arredondo A, Burke TA, Carides GW, Lemus E, Querol J.
    Rev Invest Clin; 2005; 57(3):399-405. PubMed ID: 16187699
    [Abstract] [Full Text] [Related]

  • 2. Losartan reduces the costs associated with nephropathy and end-stage renal disease from type 2 diabetes: Economic evaluation of the RENAAL study from a Canadian perspective.
    Burgess ED, Carides GW, Gerth WC, Marentette MA, Chabot I, Canadian Hypertension Society.
    Can J Cardiol; 2004 May 01; 20(6):613-8. PubMed ID: 15152291
    [Abstract] [Full Text] [Related]

  • 3. The impact of losartan on the lifetime incidence of end-stage renal disease and costs in patients with type 2 diabetes and nephropathy.
    Carides GW, Shahinfar S, Dasbach EJ, Keane WF, Gerth WC, Alexander CM, Herman WH, Brenner BM, RENAAL Investigators.
    Pharmacoeconomics; 2006 May 01; 24(6):549-58. PubMed ID: 16761903
    [Abstract] [Full Text] [Related]

  • 4. Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results.
    Remuzzi G, Ruggenenti P, Perna A, Dimitrov BD, de Zeeuw D, Hille DA, Shahinfar S, Carides GW, Brenner BM, RENAAL Study Group.
    J Am Soc Nephrol; 2004 Dec 01; 15(12):3117-25. PubMed ID: 15579515
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness of losartan in diabetic nephropathy: a Greek perspective.
    Stafylas PC, Sarafidis PA, Lasaridis AN, Tsakni E, Niakas DA, Dombros NV, Grekas DM, Bakris GL.
    J Nephrol; 2007 Dec 01; 20(6):703-15. PubMed ID: 18046673
    [Abstract] [Full Text] [Related]

  • 6. Pharmaco-economic consequences of losartan therapy in patients undergoing diabetic end stage renal disease in EU and USA.
    de Portu S, Citarella A, Cammarota S, Menditto E, Mantovani LG.
    Clin Exp Hypertens; 2011 Dec 01; 33(3):174-8. PubMed ID: 21466388
    [Abstract] [Full Text] [Related]

  • 7. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA.
    Palmer AJ, Valentine WJ, Chen R, Mehin N, Gabriel S, Bregman B, Rodby RA.
    Nephrol Dial Transplant; 2008 Apr 01; 23(4):1216-23. PubMed ID: 18359872
    [Abstract] [Full Text] [Related]

  • 8. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study.
    Bakris GL, Weir MR, Shanifar S, Zhang Z, Douglas J, van Dijk DJ, Brenner BM, RENAAL Study Group.
    Arch Intern Med; 2003 Jul 14; 163(13):1555-65. PubMed ID: 12860578
    [Abstract] [Full Text] [Related]

  • 9. Use of losartan in diabetic patients in the primary care setting: review of the results in LIFE and RENAAL.
    Egan B, Gleim G, Panish J.
    Curr Med Res Opin; 2004 Dec 14; 20(12):1909-17. PubMed ID: 15701209
    [Abstract] [Full Text] [Related]

  • 10. Losartan reduces the burden and cost of ESRD: public health implications from the RENAAL study for the European Union.
    Gerth WC, Remuzzi G, Viberti G, Hannedouche T, Martinez-Castelao A, Shahinfar S, Carides GW, Brenner B.
    Kidney Int Suppl; 2002 Dec 14; (82):S68-72. PubMed ID: 12410859
    [Abstract] [Full Text] [Related]

  • 11. [Economic impact of Losartan use in type 2 diabetic patients with nephropathy].
    González F F, Fuentes C V, Castro H C, Santelices L JP, Lorca H E.
    Rev Med Chil; 2009 May 14; 137(5):634-40. PubMed ID: 19701552
    [Abstract] [Full Text] [Related]

  • 12. Losartan reduces the costs of diabetic end-stage renal disease: an Asian perspective.
    Seng WK, Hwang SJ, Han DC, Teong CC, Chan J, Burke TA, Carides GW, Choi YJ.
    Nephrology (Carlton); 2005 Oct 14; 10(5):520-4. PubMed ID: 16221106
    [Abstract] [Full Text] [Related]

  • 13. The cost-effectiveness of losartan in type 2 diabetics with nephropathy in Switzerland--an analysis of the RENAAL study.
    Szucs TD, Sandoz MS, Keusch GW.
    Swiss Med Wkly; 2004 Aug 07; 134(31-32):440-7. PubMed ID: 15389347
    [Abstract] [Full Text] [Related]

  • 14. Economic evaluation of angiotensin receptor blockers in type 2 diabetes, hypertension, and nephropathy.
    Ravera M, Re M, Vettoretti S.
    J Am Soc Nephrol; 2006 Apr 07; 17(4 Suppl 2):S44-8. PubMed ID: 16565246
    [Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness of losartan-based therapy in patients with hypertension and left ventricular hypertrophy: a UK-based economic evaluation of the Losartan Intervention for Endpoint reduction in hypertension (LIFE) study.
    McInnes G, Burke TA, Carides G.
    J Hum Hypertens; 2006 Jan 07; 20(1):51-8. PubMed ID: 16357874
    [Abstract] [Full Text] [Related]

  • 16. Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies.
    Carr AA, Kowey PR, Devereux RB, Brenner BM, Dahlöf B, Ibsen H, Lindholm LH, Lyle PA, Snapinn SM, Zhang Z, Edelman JM, Shahinfar S.
    Am J Cardiol; 2005 Dec 01; 96(11):1530-6. PubMed ID: 16310435
    [Abstract] [Full Text] [Related]

  • 17. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.
    Eijkelkamp WB, Zhang Z, Remuzzi G, Parving HH, Cooper ME, Keane WF, Shahinfar S, Gleim GW, Weir MR, Brenner BM, de Zeeuw D.
    J Am Soc Nephrol; 2007 May 01; 18(5):1540-6. PubMed ID: 17409317
    [Abstract] [Full Text] [Related]

  • 18. Recent advances in management of type 2 diabetes and nephropathy: lessons from the RENAAL study.
    Keane WF, Lyle PA, Reduction of Endpoints in NIDDM with the Angiotensin II Receptor Antagonist Losartan study.
    Am J Kidney Dis; 2003 Mar 01; 41(3 Suppl 1):S22-5. PubMed ID: 12612946
    [Abstract] [Full Text] [Related]

  • 19. Advances in the treatment of diabetic renal disease: focus on losartan.
    Rayner B.
    Curr Med Res Opin; 2004 Mar 01; 20(3):333-40. PubMed ID: 15025842
    [Abstract] [Full Text] [Related]

  • 20. Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluation.
    Herman WH, Shahinfar S, Carides GW, Dasbach EJ, Gerth WC, Alexander CM, Cook JR, Keane WF, Brenner BM.
    Diabetes Care; 2003 Mar 01; 26(3):683-7. PubMed ID: 12610022
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 21.